Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

January 10, 2025

New Haven-based biotech raises $14.5M to expand PTSD treatment program

By Andrew Larson

A New Haven-based biotech company, Nema Health, announced a $14.5 million Series A funding round that will expand its online trauma therapy program to three new states: California, Florida and Pennsylvania.

The investment, led by Deerfield Management and CVS Health Ventures, allows Nema to “expand its treatment across markets, broaden insurance coverage and continue deepening its care offerings,” Thursday’s announcement states.

Nema's existing investors, Optum Ventures, .406 Ventures and GreyMatter, also participated in the funding round.

Nema says its virtual treatment program uses cognitive processing therapy to help trauma patients, including those with PTSD, recover.

Using a peer-led therapy model, Nema’s program helps patients “challenge and modify their belief systems related to how they see their trauma, themselves and the world.”

The program aims to help patients rebuild relationships, intimacy and trust, the company said.

Nema, launched in 2023, now operates in New Jersey, New York, Connecticut, California, Massachusetts, Pennsylvania, Florida and Illinois. It plans to expand to more states this year.

"80% of people will endure trauma in their lifetimes – from domestic and sexual violence to child abuse, gun violence, car accidents, war, climate disasters and pregnancy loss – and 20% will go on to develop PTSD," said Dr. Sofia Noori, co-founder and CEO of Nema Health. "We've built Nema to bring evidence-based treatment and rapid relief to trauma survivors – helping them regain strength, find long-term healing, and build big, joyful lives."

Nema said it is in-network with several major commercial insurance plans.

Sign up for Enews

Most Recent

Most Recent

0 Comments

Order a PDF